It is the pre-screened adjuvant that shows the strongest but most safest parenteral as well as mucosal immune response when injected with an antigen. It is sterile and ready for injection. Simply mix with your source of antigen and inject to your choice of testing animal. The dose is 5 ug/mouse for IP/IN/IV and 10 ug/mouse for SC/IM/ID. It shows a potent protection activity against influenza virus either by IM or IN.
It is the pre-screened adjuvant that shows the strongest therapeutic effect in a mouse melanoma model through Th-1 and Th-2 immune system. It potentiates the effect of cancer immunotherapy when injected with an cancer antigen. The antigen and adjuvant mixture shows potent anti-cancer as well as anti-metastatic effect. It is sterile and ready for injection. Simply mix with your cancer antigen and inject to your choice of testing animal. The source of antigen can be from a peptide to tumor lysate. The dose is 5 ug/mouse for IP/IN/IV and 10 ug/mouse for SC/IM/IN. With the significant induction of Th-1 immune response, the vaccine shows potent cytolytic effect to the cancer cells through the CD8+ cells.
After all time and money consuming endeavor, the soluble epitope is recognized as processed end
product of immune system instead of identity of target pathogen. If each unique epitope and our novel
adjuvant is mixed, they form a heat stable and a potent immune stimulating nano-complex.
The complex is homogeneous with the fixed size of 400 nm which is misunderstood as a invading viral
particle to immune systems. These platform technology can be extended to diverse area of vaccines
from infectious diseases to T-cell based cancer immunotherpay.
The leading platform technology can be applied to every single vaccine development by adopting each unique epitope. The vaccine complex can be loaded with multiple epitopes target diverse serotypes of pathogen or target diseases.